TICKERNERD
Menu
VIRVIRHealthcare · Biotechnology

VIR Stock Forecast: Vir Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$9.24
+2.67% on the day

The 10 Wall Street analysts covering Vir Biotechnology, Inc. hold a median 12-month price target of $20 — +116.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.6B
Ticker Nerd rank
93 / 100
Median analyst target
$20
Analysts covering
10
Total return, dividends reinvested
1W
+4.8%
1M
−2.6%
YTD
+53.2%
1Y
+108.1%
From 52W high
−16.7%
From 52W low
+111.9%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VIR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vir Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Volatility
88
Value
87
Quality
86
Momentum
78
Revisions
64
Issuance
49
Accruals
47
Size
40

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VIR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VIR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26VIRHigh $30Median $20Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $15Median $20High $30

The green dot is the last close — the median target sits +116.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 June 2026Morgan StanleyMaintainsOverweight$23 → $27
3 June 2026Leerink PartnersMaintainsOutperform—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026BarclaysMaintainsOverweight—
24 Feb 2026Evercore ISI GroupMaintainsOutperform—
24 Feb 2026Morgan StanleyMaintainsOverweight—
24 Feb 2026NeedhamMaintainsBuy—
9 Feb 2026NeedhamReiteratesBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025Evercore ISI GroupInitiatesOutperform—
27 Aug 2025B of A SecuritiesUpgradeBuy—
11 July 2025Raymond JamesInitiatesOutperform—
22 May 2025NeedhamReiteratesBuy—
12 May 2025NeedhamMaintainsBuy—
17 Apr 2025Goldman SachsMaintainsBuy—
28 Feb 2025BarclaysMaintainsOverweight—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
27 Feb 2025NeedhamReiteratesBuy—
31 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VIR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Vir Biotechnology, Inc. (VIR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
5.2×

Cheaper than 24% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
−4.2×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
19582.5%

Higher than 99% of US stocks

Earnings growth (YoY)
23075.1%

Higher than 99% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
30.7%

Higher than 88% of US stocks

Net margin
−83.0%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 28% of US stocks

Return on assets
−14.5%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VIR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VIRVir Biotechnology, Inc.$1.6B
93
ABSIAbsci Corp.$1.6B
34
XERSXeris Biopharma Holdings, Inc.$1.6B
85
JBIOJade Biosciences, Inc.$1.6B
26
LBRXLB Pharmaceuticals, Inc.$1.5B
7
INVAInnoviva, Inc.$1.6B
85
BCAXBicara Therapeutics, Inc.$1.6B
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vir Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VIR news & analysis

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Vir Biotechnology, Inc. held its second-quarter 2026 earnings call, and a transcript of that call has now been published by Seeking Alpha. The item presents the discussion from the company's earnings presentation without stating specific results or figures.

Why it matters — A VIR watcher would care because the earnings call transcript offers management's commentary on the company's quarterly performance.

Vir Biotechnology Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Vir Biotechnology reported its second-quarter 2026 results along with updates on its chronic hepatitis delta and oncology programs, including completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.

Why it matters — The completed hepatitis delta enrollment and expanded VIR-5500 development signal progress in advancing key pipeline programs toward anticipated data readouts.

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Zacks Investment Research · 6 Aug 2026negative

Vir Biotechnology reported Q2 earnings of $0.47 per share, falling short of the Zacks Consensus Estimate of $0.83 per share. This compares with a loss of $0.80 per share in the same quarter a year ago.

Why it matters — The earnings miss versus analyst expectations signals that the company's quarterly results came in below consensus forecasts, which is relevant for investors tracking VIR's performance.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Business Wire · 5 Aug 2026positive

Vir Biotechnology issued a corporate update and reported financial results for the second quarter ended June 30, 2026. In its update, the company highlighted the hepatitis delta virus treatment landscape, noting that at EASL experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with chronic hepatitis D.

Why it matters — A VIR watcher would care because the update centers on the company's hepatitis delta virus program and whether its therapies could contribute to improved awareness, testing, and access to care in the CHD community.

Vir Biotechnology Announces Chief Financial Officer Transition

Business Wire · 24 July 2026neutral

Vir Biotechnology announced that Brent Sabatini has been appointed Interim Principal Financial Officer, replacing Jason O'Byrne who is leaving the company. The company has initiated a search for a permanent Chief Financial Officer.

Why it matters — A change in the CFO role introduces a period of leadership transition in a key financial position, and investors will watch for the appointment of a permanent CFO.

FAQ

Frequently asked questions about VIR stock

What is the VIR stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Vir Biotechnology, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VIR stock a buy right now?

Of the 10 analysts covering Vir Biotechnology, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vir Biotechnology, Inc. 93 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VIR?

As at 15 Aug 2026, Vir Biotechnology, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will VIR stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +116.5% from the last close, and Ticker Nerd's factor model ranks Vir Biotechnology, Inc. 93 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VIR stock forecast for 2030?

No analyst covering Vir Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.

How has VIR stock performed over the past year?

Vir Biotechnology, Inc. returned +108.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vir Biotechnology, Inc. do?

Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer.

What is the latest news on VIR?

The most recent item we track (Seeking Alpha, 6 Aug 2026): "Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript". Vir Biotechnology, Inc. held its second-quarter 2026 earnings call, and a transcript of that call has now been published by Seeking Alpha. The item presents the discussion from the company's earnings presentation without stating specific results or figures.

Company

About Vir Biotechnology, Inc.

Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the immune system against unmet medical needs. Its lead program features the combination of tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a siRNA targeting hepatitis B virus, in Phase 3 trials through the ECLIPSE registrational program for chronic hepatitis delta virus. In oncology, Vir Biotechnology advances PRO-XTEN dual-masked T-cell engagers, including VIR-5500 targeting PSMA for metastatic castration-resistant prostate cancer, VIR-5818 for HER2-expressing tumors, and VIR-5525 for EGFR-expressing solid tumors, all in Phase 1 development. Preclinical efforts target influenza, RSV, human metapneumovirus, HPV, HIV, and other indications. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology focuses on immunology-driven innovation across infectious diseases and oncology to deliver potentially transformative medicines.

CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. · 367 employees · United States · https://www.vir.bio